Literature DB >> 23035065

Tumefactive multiple sclerosis lesions under fingolimod treatment.

Femke Visser1, Mike P Wattjes, Petra J W Pouwels, Wim H J P Linssen, Bob W van Oosten.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23035065     DOI： 10.1212/WNL.0b013e3182735cb3

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  27 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

Review 3.  Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Authors:  Jiwon Oh; Paul W O'Connor
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

Review 4.  Regulation of lymphocyte trafficking in central nervous system autoimmunity.

Authors:  Mohamed Oukka; Estelle Bettelli
Journal:  Curr Opin Immunol       Date:  2018-09-27       Impact factor: 7.486

5.  Fingolimod after natalizumab and the risk of short-term relapse.

Authors:  Vilija G Jokubaitis; Vivien Li; Tomas Kalincik; Guillermo Izquierdo; Suzanne Hodgkinson; Raed Alroughani; Jeannette Lechner-Scott; Alessandra Lugaresi; Pierre Duquette; Marc Girard; Michael Barnett; Francois Grand'Maison; Maria Trojano; Mark Slee; Giorgio Giuliani; Cameron Shaw; Cavit Boz; Daniele L A Spitaleri; Freek Verheul; Jodi Haartsen; Danny Liew; Helmut Butzkueven
Journal:  Neurology       Date:  2014-03-07       Impact factor: 9.910

6.  Initiating oral fingolimod treatment in patients with multiple sclerosis.

Authors:  Barry A Singer
Journal:  Ther Adv Neurol Disord       Date:  2013-07       Impact factor: 6.570

Review 7.  MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update.

Authors:  M P Wattjes; M D Steenwijk; M Stangel
Journal:  Clin Neuroradiol       Date:  2015-07-23       Impact factor: 3.649

8.  Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammation.

Authors:  Hsing-Chuan Tsai; Yingxiang Huang; Christopher S Garris; Monica A Moreno; Christina W Griffin; May H Han
Journal:  JCI Insight       Date:  2016-06-16

Review 9.  Targeting cells in motion: migrating toward improved therapies.

Authors:  Jason W Griffith; Andrew D Luster
Journal:  Eur J Immunol       Date:  2013-05-13       Impact factor: 5.532

Review 10.  Defining and scoring response to IFN-β in multiple sclerosis.

Authors:  Maria Pia Sormani; Nicola De Stefano
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.